What are the two FDA approved CAR-T cell therapy?

Tisagenlecleucel: CD19-targeted T cells. Trade Name: Kymriah — Approved in August 2017 for the treatment of acute lymphocytic leukemia (ALL) of pro-B cells in pediatric and young adult patients — Survival rate after 3 months : 83% in relapsed ALL patients Axicabtagene: CD19-targeted T cells. Trade name: Yescarta — Approved by the FDA in October 2017 for the treatment of Diffuse Large B cell Lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma — Indicated in adults who failed 2 previous therapies — Side effects: cytokine release syndrome and neurologic events, potential fatal